- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3, Placebo - Part 1 Group 4, ISB 830 - Part 2 Group 5, Placebo - Part 2 Group 6
- Drug
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
- Drug
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
- Conditions
- HER2 Expressing Solid Tumours
- Interventions
- CD3/HER2 bispecific monoclonal antibody
- Drug
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Fairway, Kansas • Detroit, Michigan • Dallas, Texas + 1 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ISB 1342
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Baltimore, Maryland • Rochester, Minnesota + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- GBR 830, Placebo
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ISB 2001
- Drug
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more